UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

Annals of oncology, 2013-02, Vol.24 (2), p.355-361

2013

Volltextzugriff (PDF)

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)

Annals of oncology, 2005-05, Vol.16 (5), p.707-715

2005

Volltextzugriff (PDF)

Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27

European journal of cancer (1990), 2018-02, Vol.90, p.19-25

2018

Volltextzugriff (PDF)

Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer

Journal of clinical oncology, 2001-02, Vol.19 (3), p.881-894

2001

Volltextzugriff (PDF)

Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy

British journal of cancer, 2014-11, Vol.111 (11), p.2046-2050

2014

Volltextzugriff (PDF)

The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats

Bone (New York, N.Y.), 2004-03, Vol.34 (3), p.384-392

2004

Volltextzugriff (PDF)

Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma

Annals of oncology, 2008-01, Vol.19 (1), p.62-67

2008

Volltextzugriff (PDF)

randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women

Breast cancer research and treatment, 2011-04, Vol.126 (2), p.453-461

2011

Volltextzugriff (PDF)

Inhibitors of carbohydrate processing: A new class of anticancer agents

Clinical cancer research, 1995-09, Vol.1 (9), p.935-944

1995

Volltextzugriff (PDF)

randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women

Breast cancer research and treatment, 2010-04, Vol.120 (2), p.427-435

2010

Volltextzugriff (PDF)

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

Annals of oncology, 2008-05, Vol.19 (5), p.877-882

2008

Volltextzugriff (PDF)

Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies

Clinical cancer research, 1997-07, Vol.3 (7), p.1077-1086

1997

Volltextzugriff (PDF)

Male breast carcinoma : A review of 229 patients who presented to the Princess Margaret Hospital during 40 years : 1955-1996

Cancer, 1999-02, Vol.85 (3), p.629-639

1999

Volltextzugriff (PDF)

Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer

Annals of oncology, 2006-11, Vol.17 (11), p.1637-1643

2006

Volltextzugriff (PDF)

Current perspectives on radiation-induced breast cancer

Journal of clinical oncology, 1998-01, Vol.16 (1), p.338-347

1998

Volltextzugriff (PDF)

Randomized Phase III Trial Comparing the New Potent and Selective Third-Generation Aromatase Inhibitor Vorozole With Megestrol Acetate in Postmenopausal Advanced Breast Cancer Patients

Journal of clinical oncology, 1999-01, Vol.17 (1), p.52-63

1999

Volltextzugriff (PDF)

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

Annals of oncology, 2017-07, Vol.28 (7), p.1560-1568

2017

Volltextzugriff (PDF)

Evolving perspectives in contralateral breast cancer

European Journal of Cancer, 1998-12, Vol.34 (13), p.2000-2009

1998

Volltextzugriff (PDF)

Risks versus benefits in the clinical application of aromatase inhibitors

Endocrine-related cancer, 1999-06, Vol.6 (2), p.325-332

Goss, P E

1999

Volltextzugriff (PDF)

Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011

Breast (Edinburgh), 2017-02, Vol.31, p.197-201

2017

Volltextzugriff (PDF)

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

Journal of clinical oncology, 1996-01, Vol.14 (1), p.66-69

1996

Volltextzugriff (PDF)

Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade

Journal of clinical oncology, 1996-12, Vol.14 (12), p.3141-3147

1996

Volltextzugriff (PDF)

New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole – Analyses from NCIC CTG MA.17

Breast (Edinburgh), 2016-06, Vol.27, p.99-104

2016

Volltextzugriff (PDF)

Examination of POU homeobox gene expression in human breast cancer cells

International journal of cancer, 1999-03, Vol.81 (1), p.104-112

1999

Volltextzugriff (PDF)

Conclusions regarding relative cost–utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature

Annals of oncology, 2007-01, Vol.18 (1), p.197-198

2007

Volltextzugriff (PDF)

1 – 25 von 714

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(630)
Mit Volltextzugriff
(605)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)

Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27

Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer

Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy

The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats

Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma

randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women

Inhibitors of carbohydrate processing: A new class of anticancer agents

randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies

Male breast carcinoma : A review of 229 patients who presented to the Princess Margaret Hospital during 40 years : 1955-1996

Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer

Current perspectives on radiation-induced breast cancer

Randomized Phase III Trial Comparing the New Potent and Selective Third-Generation Aromatase Inhibitor Vorozole With Megestrol Acetate in Postmenopausal Advanced Breast Cancer Patients

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

Evolving perspectives in contralateral breast cancer

Risks versus benefits in the clinical application of aromatase inhibitors

Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade

New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole – Analyses from NCIC CTG MA.17

Examination of POU homeobox gene expression in human breast cancer cells

Conclusions regarding relative cost–utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature

Suchergebnisse filtern